Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

Factors Affecting Drug Response: Overview

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Where are we in our understanding of the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines?

Biologicals : journal of the International Association of Biological Standardization·2016

Same author

Synthesis of stable isotope labelled internal standards for drug-drug interaction (DDI) studies.

Bioorganic & medicinal chemistry·2012

Same author

[What has become of extemporaneous mixtures?].

Annales de dermatologie et de venereologie·2007

Same author

Insulin like growth factor regulation of body mass in breastfed and milk formula fed infants. Data from the E.U. Childhood Obesity Programme.

Advances in experimental medicine and biology·2005

Same author

[Medicines for children: time to act!].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2005

Same author

Study design in osteoporosis: a European perspective.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2003

Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018

Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018

Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018

Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018

Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018

Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018

See all related articles

Search research articles

Related Experiment Videos

[Better medicines for children].

¹L'Huderf.

Revue Medicale De Bruxelles

|August 9, 2011

Summary

This summary is machine-generated.

A new European Regulation encourages pharmaceutical companies to develop pediatric drugs. This initiative requires collaboration among patients, healthcare providers, and regulatory bodies to ensure successful pediatric drug indications.

Related Experiment Videos

Area of Science:

Pharmacology
Pediatric Medicine
Regulatory Science

Context:

European Union regulation promoting pediatric drug development.
Addresses the historical lack of approved medicines for children.
Requires adaptation of pharmaceutical industry practices.

Purpose:

To incentivize pharmaceutical companies to research and develop new drugs for pediatric populations.
To ensure children have access to safe and effective medicines tailored to their needs.
To fulfill the requirements of the European Regulation on Paediatric Medicines.

Summary:

The European Regulation mandates pharmaceutical companies to develop pediatric drug formulations.
Involves children and parents in clinical trials.
Requires pediatricians to monitor trials, ethical committees to provide guidance, and public health authorities to support the system.
Aims to achieve a comprehensive set of pediatric drug indications.

Impact:

Substantial consequences for all stakeholders involved in pediatric drug development.
Increased participation of children in clinical research.
Innovation in adapted pharmaceutical formulations for pediatric use.
Enhanced collaboration between industry, ethics committees, and public health authorities.